About: Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab
Creator	Smith, Zachary Peters, Michael Ramesh, Mayur Swiderek, Jennifer Vahia, Amit Bianchini, Monica Johnson, Joseph Griebe, Kristin Hencken, Laura Jones, Mathew Morrison, Austin Stine, John To, Long
source	Elsevier; Medline; PMC
abstract	Coronavirus disease 2019 (COVID-19) can progress to cytokine storm that is associated with organ dysfunction and death. The purpose of the present study is to determine clinical characteristics associated with 28 day in-hospital survival in patients with coronavirus disease 2019 (COVID-19) that received tocilizumab. This was a retrospective observational cohort study conducted at a five hospital health system in Michigan, United States. Adult patients with confirmed COVID-19 that were admitted to the hospital and received tocilizumab for cytokine storm from March 1, 2020 through April 3, 2020 were included. Patients were grouped into survivors and non-survivors based on 28 day in-hospital mortality. Study day 0 was defined as the day tocilizumab was administered. Factors independently associated with in-hospital survival at 28 days after tocilizumab administration were assessed. Epidemiologic, demographic, laboratory, prognostic scores, treatment, and outcome data were collected and analyzed. Clinical response was collected and defined as a decline of two levels on a six-point ordinal scale of clinical status or discharged alive from the hospital. Of the 81 patients included, the median age was 64 (58–71) years and 56 (69.1%) were male. The 28 day in-hospital mortality was 43.2%. There were 46 (56.8%) patients in the survivors and 35 (43.2%) in the non-survivors group. On study day 0 no differences were noted in demographics, clinical characteristics, severity of illness scores, or treatments received between survivors and non-survivors. C-reactive protein was significantly higher in the non-survivors compared to survivors. Compared to non-survivors, recipients of tocilizumab within 12 days of symptom onset was independently associated with survival (adjusted OR: 0.296, 95% CI: 0.098–0.889). SOFA score ≥8 on day 0 was independently associated with mortality (adjusted OR: 2.842, 95% CI: 1.042–7.753). Clinical response occurred more commonly in survivors than non-survivors (80.4% vs. 5.7%; p < 0.001). Improvements in the six-point ordinal scale and SOFA score were observed in survivors after tocilizumab. Early receipt of tocilizumab in patients with severe COVID-19 was an independent predictor for in-hospital survival at 28 days.
has issue date	2020-07-03(xsd:dateTime)
bibo:doi	10.1016/j.jaut.2020.102512
bibo:pmid	32646770
has license	no-cc
sha1sum (hex)	f8e62203e1e0b20eb0c53666ecf9a4e27d182db9
schema:url	https://doi.org/10.1016/j.jaut.2020.102512
resource representing a document's title	Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab
has PubMed Central identifier	PMC7332925
has PubMed identifier	32646770
schema:publication	J Autoimmun
resource representing a document's body	covid:f8e62203e1e0b20eb0c53666ecf9a4e27d182db9#body_text
is schema:about of	named entity 'adults' named entity 'coronavirus disease 2019' named entity 'IL-1 receptor antagonist' named entity 'nasal cannula' named entity 'COVID' named entity 'immunomodulatory' named entity 'Tcell' named entity 'D-dimer' named entity 'COVID-19' named entity 'respiratory failure' named entity 'laboratory tests' named entity 'COVID-19' named entity 'retrospective cohort study' named entity 'ritonavir' named entity 'mechanical ventilation' named entity 'hemophagocytic lymphohistiocytosis' named entity 'blood pressure' named entity 'invasive mechanical ventilation' named entity 'D-Dimer' named entity 'Henry Ford' named entity 'triglyceride levels' named entity 'LDH' named entity 'SOFA score' named entity 'SOFA score' named entity 'IL-6 receptor' named entity 'assay' named entity 'ARDS' named entity 'tocilizumab' named entity 'COVID' named entity 'biphasic' named entity 'monotherapy' named entity 'COVID' named entity 'antimicrobials' named entity 'CRS' named entity 'hypertriglyceridemia' named entity 'clinical microbiology laboratory' named entity 'cytokine storm' named entity 'ECMO' named entity 'antivirals' named entity 'obesity' named entity '28 days' named entity 'supplemental oxygen' named entity 'CRS' named entity 'China' named entity 'COVID' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'IBM' named entity 'lung' named entity 'immunomodulatory' named entity 'D-Dimer' named entity 'ferritin' named entity 'supplemental oxygen' named entity 'cytokine storm' named entity 'LDH' named entity 'tocilizumab' named entity 'fraction of inspired oxygen' named entity 'IL-6' named entity 'obesity' named entity 'nasal cannula' named entity 'Hypertriglyceridemia' named entity 'off-label' named entity 'COVID-19' named entity 'hypoxia' named entity 'ARDS' named entity '4.7' named entity 'tocilizumab' named entity 'cytokine storm' named entity 'statistically significant'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software